Three year IGF-I treatment of children with Laron syndrome.
about
Endocrine parameters and phenotypes of the growth hormone receptor gene disrupted (GHR-/-) mouseA mammalian model for Laron syndrome produced by targeted disruption of the mouse growth hormone receptor/binding protein gene (the Laron mouse)Human conditions of insulin-like growth factor-I (IGF-I) deficiencyElevated levels of insulin-like growth factor (IGF)-I in serum rescue the severe growth retardation of IGF-I null mice.Insulin-like growth factor 1 (IGF-1): a growth hormoneElevated serum levels of IGF-1 are sufficient to establish normal body size and skeletal properties even in the absence of tissue IGF-1.Changes in insulin-like growth factor-I and -II associated with fat but not lean mass in early old age.Systemically delivered insulin-like growth factor-I enhances mesenchymal stem cell-dependent fracture healing.Insulin-like growth factor-I (rhIGF-I) therapy of short stature.Recombinant human insulin-like growth factor-I therapy for children with growth disorders.Serum IGF-1 is insufficient to restore skeletal size in the total absence of the growth hormone receptor.Mecasermin (recombinant human insulin-like growth factor I).The role of insulin-like growth factor during a postischemic period - new insights into pathophysiologic pathways in cardiac tissue.Treatment of dwarfism with recombinant human insulin-like growth factor-1.Recombinant human IGF-1 (insulin-like growth factor) therapy: where do we stand today?Height, weight, body mass index and ocular biometry in patients with sickle cell disease.Hypoglycemia due to hormone deficiencies.Serum insulin-like growth factor-I (IGF-I) levels during long-term IGF-I treatment of children and adults with primary GH resistance (Laron syndrome).Insulin-like growth factors: actions on the skeleton.Serum leptin in obese patients with Laron syndrome before and during IGF-I treatment.
P2860
Q24613998-E934E55F-7391-4396-B69C-66F3C0D6AB3EQ24654776-6E6E161F-2717-4DDC-B095-D118184CC540Q26822806-ED3CD049-EEEA-4D88-98FA-B81E57E82044Q33644001-4535F808-2B3D-44D5-AFFC-EEA7297DF4F6Q33918809-68FE5227-5A1B-4152-890E-A8539DF2C314Q35155509-8452BE8E-D92B-4D84-9FA7-44C2DA1E8400Q36532909-B0C3137C-1618-4F78-8190-8D1AC1D4A427Q37119783-22FA9612-7668-4B4D-B51E-A3B56A338FC5Q37192175-C8E2DDB1-9A7E-46C2-81FA-08FE3797660DQ37344647-12C35D9F-1EAA-4C26-B478-F07BCCADD047Q37349402-F6851334-1168-49BC-B215-75BE5F5528F4Q37386995-0E46FFC1-5CF9-4761-B90A-BE9B790F4A6CQ37608512-09DEC93A-3817-4D50-A67F-DCF77B8B034CQ37641081-CF874E68-0DB8-4699-8257-D1B2F357A630Q37957047-D4668A81-693E-4FD2-8C40-59C92163EA82Q43919871-222E5E47-373F-4492-B382-E383B38C9391Q47920692-0CC277B4-1F5C-4F01-869D-23F5D70306AFQ51562510-1EC672CF-66FD-45B0-98EE-39055CE7D8B7Q52329568-99438537-A05B-4DB9-A56B-3342E36D58D2Q54115399-BD319FD5-16E9-43DF-AD44-951C3E2113F5
P2860
Three year IGF-I treatment of children with Laron syndrome.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh-hant
name
Three year IGF-I treatment of children with Laron syndrome.
@en
Three year IGF-I treatment of children with Laron syndrome.
@nl
type
label
Three year IGF-I treatment of children with Laron syndrome.
@en
Three year IGF-I treatment of children with Laron syndrome.
@nl
prefLabel
Three year IGF-I treatment of children with Laron syndrome.
@en
Three year IGF-I treatment of children with Laron syndrome.
@nl
P2860
P1476
Three year IGF-I treatment of children with Laron syndrome.
@en
P2093
P2860
P304
P356
10.1515/JPEM.1995.8.3.149
P577
1995-07-01T00:00:00Z